Mylan Can't Launch Doryx Generic Just Yet

Law360, New York (February 8, 2012, 7:08 PM EST) -- A New Jersey federal judge on Wednesday blocked Mylan Pharmaceuticals Inc. from launching a generic version of Warner Chilcott PLC’s anti-acne medication Doryx.

U.S. District Judge William J. Martini issued a temporary restraining order, with the agreement of both parties, in order for the court to complete the impending trial, consider the evidence and render a decision.

Mylan had sought to market a generic version of the Doryx 150-milligram doxycycline hyclate delayed-release tablet products, according to the suit.

Judge Martini also issued an identical TRO in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.